abstract |
The present invention relates to methods for treating, delaying, slowing the progression of, and/or preventing kidney disease, comprising administering to a subject in need thereof a therapeutically effective amount of a synergistic treatment comprising consisting of, consisting of, or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-γ Agonists; and the present invention relates to methods for treating fatty liver disease (eg, NASH or NAFLD), delaying fatty liver disease, slowing the progression of fatty liver disease, and/or preventing fatty liver disease, the method comprising administering to a subject in need thereof A therapeutically effective amount of canagliflozin. |